Cannabidiol
- Generic Name
- Cannabidiol
- Brand Names
- Epidiolex, Sativex, Epidyolex
- Drug Type
- Small Molecule
- Chemical Formula
- C21H30O2
- CAS Number
- 13956-29-1
- Unique Ingredient Identifier
- 19GBJ60SN5
- Background
Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investig...
- Indication
When used in combination with delta-9-tetrahydrocannabinol as the product Sativex, cannabidiol was given a standard marketing authorization (ie. a Notice of Compliance (NOC)) by Health Canada for the following indications:
...
- Associated Conditions
- Multiple Sclerosis, Seizures, Severe Pain, Moderate Pain
- Associated Therapies
- -
Latest Stock News & Market Updates
Jazz Pharmaceuticals (JAZZ) is a global biopharmaceutical company focusing on sleep, hematology/oncology, and pain, with notable products like Xyrem, Xywav, Zepzelca, Rylaze, and Epidiolex. In 2023, it achieved $3.8 billion in revenue, completed a Phase 3 trial for Zepzelca, and advanced zanidatamab development. With $1.6 billion in cash and $5.8 billion in debt, Jazz continues to innovate through R&D and strategic acquisitions, partnering with BeiGene and Life Science Cares.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath